Top Page
Astec Lifesciences Limited
(ASTEC)
Astec Lifesciences Limited (ASTEC) vs. iShares MSCI India ETF (INDA)
Astec Lifesciences Limited Business Overview & Revenue Model
Astec Lifesciences Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.03B | 3.81B | 4.58B | 6.28B | 6.77B | 5.55B |
| Gross Profit | 973.81M | -685.16M | 1.33B | 2.27B | 2.86B | 2.10B |
| EBITDA | -271.65M | -662.07M | -2.69M | 893.14M | 1.65B | 1.19B |
| Net Income | -1.28B | -1.35B | -469.30M | 255.65M | 898.59M | 650.49M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 8.81B | 9.75B | 9.79B | 8.97B | 6.78B |
| Cash, Cash Equivalents and Short-Term Investments | 5.75M | 8.55M | 16.47M | 27.54M | 33.44M | 15.42M |
| Total Debt | 0.00 | 5.55B | 4.94B | 3.41B | 2.79B | 1.87B |
| Total Liabilities | -2.35B | 6.46B | 6.05B | 5.60B | 5.00B | 3.68B |
| Stockholders Equity | 2.35B | 2.35B | 3.69B | 4.19B | 3.96B | 3.09B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -302.20M | -1.25B | -426.03M | -803.74M | -1.11B |
| Operating Cash Flow | 0.00 | -83.99M | 102.21M | 746.56M | 236.04M | -81.62M |
| Investing Cash Flow | 0.00 | -152.30M | -1.35B | -1.13B | -1.04B | -731.10M |
| Financing Cash Flow | 0.00 | 237.33M | 1.25B | 377.70M | 804.77M | 813.36M |
Astec Lifesciences Limited Technical Analysis
Astec Lifesciences Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹12.62B | 38.83 | ― | 2.50% | -10.71% | -40.89% | |
64 Neutral | ₹16.00B | 30.60 | ― | 0.24% | 10.70% | 32.65% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
56 Neutral | ₹26.62B | 25.34 | ― | 0.88% | 2.73% | -11.40% | |
48 Neutral | ₹11.82B | 385.17 | ― | 0.35% | ― | ― | |
38 Underperform | ₹14.14B | ― | ― | ― | 1.54% | -8.04% |
Astec Lifesciences Limited Corporate Events
Astec LifeSciences Limited, a company involved in the life sciences sector, has announced the resignation of Mr. Vivek Ramchandra Thorat from his position as Associate Vice President – Operations, effective from the close of working hours on October 24, 2025. This change in senior management is due to Mr. Thorat’s decision to pursue opportunities outside the company. The company has accepted his resignation and relieved him of his duties.
Astec LifeSciences Limited has announced a Postal Ballot Notice to seek approval from its members for certain resolutions. The company is utilizing electronic means for voting, facilitated by the National Securities Depository Limited, and has made the necessary documents available on its website and other relevant platforms. This move is in compliance with regulatory requirements and reflects the company’s commitment to maintaining transparent communication with its stakeholders.
Astec LifeSciences Limited, a company in the life sciences sector, has announced the re-appointment of Mr. Nandkumar Dhekne as a Non-Executive & Independent Director for a second term of five years, starting December 18, 2025, pending shareholder approval. Mr. Dhekne brings extensive experience in operations management and leadership in the Asia Pacific region, which is expected to bolster the company’s strategic direction and governance.
Astec LifeSciences Limited has announced the re-appointment of Ms. Anjali Gupte and Mr. Nandkumar Dhekne as Non-Executive & Independent Directors for a second term of five years, starting from December 18, 2025, pending shareholder approval. This strategic move is expected to enhance the company’s governance and leverage Mr. Dhekne’s extensive experience in operations management and leadership across Asia Pacific, potentially strengthening Astec’s market position and operational efficiency.
Astec LifeSciences Limited has announced the re-appointment of Mr. Nandkumar Dhekne as a Non-Executive & Independent Director for a second term of five years, starting from December 18, 2025, to December 17, 2030, pending shareholder approval. This decision, approved by the Board of Directors based on the Nomination and Remuneration Committee’s recommendation, underscores the company’s commitment to maintaining experienced leadership. Mr. Dhekne brings extensive experience in operations management and leadership roles across Asia Pacific, which is likely to positively influence Astec’s strategic direction and stakeholder confidence.
Astec LifeSciences Limited has announced the re-appointment of Mr. Nandkumar Dhekne as a Non-Executive & Independent Director for a second term of five years, starting from December 18, 2025, to December 17, 2030, pending shareholder approval. This decision, based on the Nomination and Remuneration Committee’s recommendation, highlights the company’s commitment to maintaining experienced leadership, as Mr. Dhekne brings extensive expertise in operations management and sales across the Asia Pacific region, which could positively impact the company’s strategic direction and stakeholder confidence.
Astec LifeSciences Limited has announced the re-appointment of Mr. Nandkumar Dhekne as a Non-Executive & Independent Director for a second term of five years, starting from December 18, 2025, subject to shareholder approval. This strategic move leverages Mr. Dhekne’s extensive experience in operations management and leadership across the Asia Pacific region, potentially strengthening the company’s governance and strategic direction.
Astec LifeSciences Limited has announced the re-appointment of Mr. Nandkumar Dhekne as a Non-Executive & Independent Director for a second term of five years, starting from December 18, 2025, to December 17, 2030, pending shareholder approval. Mr. Dhekne brings extensive experience in field services, operations management, and sales, having held senior leadership roles across the Asia Pacific region, which is expected to bolster Astec’s strategic direction and governance.
Astec LifeSciences Limited announced the outcome of its Rights Issue Committee meeting held on July 29, 2025, where they approved the allotment of 26,69,951 equity shares on a rights basis to eligible shareholders at a price of ₹890 per share. This move increases the company’s paid-up equity share capital from 1,96,11,710 to 2,22,81,661 shares, potentially strengthening its financial position and market standing.
Astec LifeSciences Limited has published its unaudited financial results for the quarter ending June 30, 2025, as approved by its Board of Directors. The results were announced through newspaper advertisements in Business Standard and Mumbai Lakshdeep, reflecting the company’s commitment to transparency and regulatory compliance.
Astec LifeSciences Limited held its 31st Annual General Meeting (AGM) on July 28, 2025, via video conferencing, where key business matters were addressed. The meeting included the presentation of financial statements and audit reports, and shareholders were provided with electronic voting facilities. The results of the voting will be announced within two working days and made available on the company’s website, reflecting the company’s commitment to transparency and stakeholder engagement.
Astec LifeSciences Limited has announced the appointment of M/s. BNP & Associates as the secretarial auditors for a five-year term starting from the financial year 2025-26. This decision, approved at the company’s 31st Annual General Meeting, is expected to enhance the company’s compliance and governance standards, potentially strengthening its market position and stakeholder confidence.
Astec LifeSciences Limited announced the approval of its unaudited financial results for the quarter ended June 30, 2025, during a board meeting held on July 28, 2025. The results, which were reviewed by the statutory auditors and received an unmodified opinion, reflect the company’s adherence to Indian Accounting Standards (IND AS) and demonstrate its commitment to transparency and regulatory compliance. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance for the specified period.